{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:19:02Z","timestamp":1778152742749,"version":"3.51.4"},"reference-count":44,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>2-Furanones have attracted great attention due to their biological activities. They also have the ability to be converted to several biologically active heterocyclic and nonheterocyclic compounds, especially as anti-cancer agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>This research aims to share in the development process of novel cytotoxic agents by synthesizing certain 2-furanone derivatives and using them as starting materials for the preparation of novel heterocyclic and non-heterocyclic compounds, then testing the synthesized derivatives for their anti-cancer activities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>All the newly synthesized compounds were fully characterized by elemental analysis, IR, Mass, and 1H-NMR spectroscopy. 18 synthesized compounds were selected by National Cancer Institute (NCI) for testing against 60 cell lines, and the active compound was tested as MAPK14 and VEGFR2-inhibitor using Staurosporine as standard.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Compound 3a showed the higher activity against several cell lines; Leukemia (SR), Non- Small Cell Lung Cancer (NCI-H460), colon cancer (HCT-116), ovarian cancer (OVCAR-4), renal cancer (786-0, ACHN and UO-31) and, finally breast cancer (T-47D). It also has better inhibition activity against MAPK14 than the used reference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Compound 3a has promising anti-cancer activities compared to the used standards and may need further modification and investigations.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573406417666210604103135","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T18:55:38Z","timestamp":1623092138000},"page":"323-336","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utility of Certain 2-Furanone Derivatives for Synthesis of Different Heterocyclic Compounds and Testing their Anti-Cancer Activity"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-1722","authenticated-orcid":true,"given":"Rania Helmy Abd","family":"El-Hameed","sequence":"first","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain-Helwan, Helwan, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hend Medhat","family":"El-Shanbaky","sequence":"additional","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain-Helwan, Helwan, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-6802","authenticated-orcid":true,"given":"Mosaad Sayed","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain-Helwan, Helwan, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1515\/hc-2015-0008","volume":"21","author":"Abou-Elmagd W.S.I.","year":"2015","unstructured":"Abou-Elmagd W.S.I.; El-Ziaty A.K.; Abdalha A.A.; Ring transformation and antimicrobial activity of indolyl-substituted 2(3H)-furanones. Heterocycl Commun 2015,21(3),179-184","journal-title":"Heterocycl Commun"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jscs.2014.05.007","volume":"19","author":"Ahmad A.","year":"2015","unstructured":"Ahmad A.; Husain A.; Khan S.A.; Mujeeb M.; Bhandari A.; Design, synthesis, molecular properties and antimicrobial activities of some novel 2(3H) pyrrolone derivatives. J Saudi Chem Soc 2015,19,340-346","journal-title":"J Saudi Chem Soc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ejmech.2005.03.012","volume":"40","author":"Husain A.","year":"2005","unstructured":"Husain A.; Khan M.S.Y.; Hasan S.M.; Alam M.M.; Synthesis, reactions and biological activity of 2-Arylidene-4-(4-phenoxy-phenyl)but-3-en-4-olides. Eur J Med Chem 2005,40,1394-1404","journal-title":"Eur J Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2298\/JSC0902103H","volume":"74","author":"Husain A.","year":"2009","unstructured":"Husain A.; Alam M.M.; Siddiqui N.; Synthesis, reactions and biological activity of 3-arylidene-5-(4-methylphenyl)-2(3H)-furanones. J Serb Chem Soc 2009,74(2),103-115","journal-title":"J Serb Chem Soc"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.ejmech.2008.10.030","volume":"44","author":"Alam M.M.","year":"2009","unstructured":"Alam M.M.; Husain A.; Hasan S.M.; Suruchi; Anwer, T. Synthesis and pharmacological evaluation of 2(3H)-furanones and 2(3H)-pyrrolones, combining analgesic and anti-inflammatory properties with reduced gastrointestinal toxicity and lipid peroxidation. Eur J Med Chem 2009,44(6),2636-2642","journal-title":"Eur J Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jsps.2015.05.002","volume":"24","author":"Khokra S.L.","year":"2016","unstructured":"Khokra S.L.; Jyoti; Chetan; Kaushik, P.; Alam, M.M.; Zaman, M.S.; Ahmad, A.; Khan, S.A.; Husain, A. Quinoline based furanones and their nitrogen analogues: Docking, synthesis and biological evaluation. Saudi Pharm J 2016,24(6),705-717","journal-title":"Saudi Pharm J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2478\/v10007-012-0037-7","volume":"62","author":"Flefel E.M.","year":"2012","unstructured":"Flefel E.M.; Abdel-Mageid R.E.; Tantawy W.A.; Ali M.A.; Amr, Ael-G. Heterocyclic compounds based on 3-(4-bromophenyl) azo-5-phenyl-2(3H)-furanone: Anti-avian influenza virus (H5N1) activity. Acta Pharm 2012,62(4),593-606","journal-title":"Acta Pharm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ejmech.2006.12.032","volume":"42","author":"Hashem A.I.","year":"2007","unstructured":"Hashem A.I.; Youssef A.S.A.; Kandeel K.A.; Abou-Elmagd W.S.I.; Conversion of some 2(3H)-furanones bearing a pyrazolyl group into other heterocyclic systems with a study of their antiviral activity. Eur J Med Chem 2007,42(7),934-939","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ardp.200700043","volume":"340","author":"Sayed H.H.","year":"2007","unstructured":"Sayed H.H.; Hashem A.I.; Yousif N.M.; El-Sayed W.A.; Conversion of 3-arylazo-5-phenyl-2(3H)-furanones into other heterocycles of anticipated biological activity. Arch Pharm (Weinheim) 2007,340(6),315-319","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4067\/S0717-97072011000300013","volume":"56","author":"Husain A.","year":"2011","unstructured":"Husain A.; Ahmad A.; Bhandari A.; Ram V.; synthesis and antitubercular activity of pyridazinone derivatives. J Chil Chem Soc 2011,56(3),778-780","journal-title":"J Chil Chem Soc"},{"key":"ref=11","first-page":"173","volume":"66","author":"Husain A.","year":"2009","unstructured":"Husain A.; Alam M.M.; Hasan S.M.; Yar M.S.; 2(3H)-furanones and 2(3H)-pyrrolones: synthesis and antimycobacterial evaluation. Acta Poloniae Pharmaceutica and Drug Research 2009,66(2),173-180","journal-title":"Acta Poloniae Pharmaceutica and Drug Research"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/jhet.2401","volume":"53","author":"Abou-Elmagd W.S.I.","year":"2016","unstructured":"Abou-Elmagd W.S.I.; Hashem A.I.; Synthesis and antitumor activity evaluation of some novel fused and spiro heterocycles derived from a 2(3H)-furanone derivative. J Heterocycl Chem 2016,53,202-208","journal-title":"J Heterocycl Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/00397911.2016.1193755","volume":"46","author":"Abou-Elmagd W.S.I.","year":"2016","unstructured":"Abou-Elmagd W.S.I.; EL-Ziaty, A.K.; El-Zahar, M.I.; Ramadan, S.K.; Hashem, A.I. synthesis and antitumor activity evaluation of some N-Heterocycles derived from pyrazolyl-substituted 2(3H)-furanone. Synth Commun 2016,46(14),1197-1208","journal-title":"Synth Commun"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/cbdd.13183","volume":"92","author":"Wu Y.C.","year":"2018","unstructured":"Wu Y.C.; Cao L.; Mei W.J.; Wu H.Q.; Luo S.H.; Zhan H.Y.; Wang Z.Y.; Bis-2(5H)-furanone derivatives as new anticancer agents: Design, synthesis, biological evaluation, and mechanism studies. Chem Biol Drug Des 2018,92(1),1232-1240","journal-title":"Chem Biol Drug Des"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/926723","volume":"926723","author":"Liu G.","year":"2013","unstructured":"Liu G.; Guan Y.; Wu Y.; Liu H.; Synthesis and biological evaluation of novel &#x3B3;-alkylidene butenolides. Hindawi Publishing Corporation J Chem 2013,926723,1-8","journal-title":"Hindawi Publishing Corporation J Chem"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2017.08.005","volume":"139","author":"Wu Y.","year":"2017","unstructured":"Wu Y.; Luo S.; Mei W.; Cao L.; Wu H.; Wang Z.; Synthesis and biological evaluation of 4-biphenylamino-5-halo-2(5H)-furanones as potential anticancer agents. Eur J Med Chem 2017,139,84-94","journal-title":"Eur J Med Chem"},{"key":"ref=17","first-page":"6170","volume":"61","author":"Lane M.E.","year":"2001","unstructured":"Lane M.E.; Yu B.; Rice A.; Lipson K.E.; Liang C.; Sun L.; Tang C.; McMahon G.; Pestell R.G.; Wadler S.; A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001,61(16),6170-6177","journal-title":"Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2217\/nnm.15.66","volume":"10","author":"Jin X.","year":"2015","unstructured":"Jin X.; Wang Y.; Tan L.; He Y.; Peng J.; Hai L.; Wu Y.; Qian Z.; An efficient injectable formulation with block copolymer micelles for hydrophobic antitumor candidate-pyridazinone derivatives. Nanomedicine (Lond) 2015,10(14),2153-2165","journal-title":"Nanomedicine (Lond)"},{"key":"ref=19","author":"Martinez-Botella G.","year":"2005","unstructured":"Martinez-Botella G.; Hale M.; Maltais F.; Tang Q.; Straub J.; pyrrole compounds as inhibtors of ERK protein kinase , synthesis and intermediates thereto Canadian intellectual property office, patent 2005","journal-title":"pyrrole compounds as inhibtors of ERK protein kinase , synthesis and intermediates thereto Canadian intellectual property office, patent"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.bmcl.2010.10.128","volume":"21","author":"Tynebor R.M.","year":"2011","unstructured":"Tynebor R.M.; Chen M.H.; Natarajan S.R.; O\u2019Neill E.A.; Thompson J.E.; Fitzgerald C.E.; O\u2019Keefe S.J.; Doherty J.B.; Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1. Bioorg Med Chem Lett 2011,21(1),411-416","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","volume":"7","author":"Coghlan M.P.","year":"2000","unstructured":"Coghlan M.P.; Culbert A.A.; Cross D.A.; Corcoran S.L.; Yates J.W.; Pearce N.J.; Rausch O.L.; Murphy G.J.; Carter P.S.; Roxbee Cox L.; Mills D.; Brown M.J.; Haigh D.; Ward R.W.; Smith D.G.; Murray K.J.; Reith A.D.; Holder J.C.; Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000,7(10),793-803","journal-title":"Chem Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.bmcl.2013.02.027","volume":"23","author":"Elagawany M.","year":"2013","unstructured":"Elagawany M.; Ibrahim M.A.; Ali Ahmed H.E.; El-Etrawy A.; Sh.; Ghiaty, A.; Abdel-Samii, Z.K.; El-Feky, S.A.; Bajorath, J. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors. Bioorg Med Chem Lett 2013,23(7),2007-2013","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/1061186X.2019.1703189","volume":"28","author":"Kuznietsova H.","year":"2020","unstructured":"Kuznietsova H.; Dziubenko N.; Byelinska I.; Hurmach V.; Bychko A.; Lynchak O.; Milokhov D.; Khilya O.; Rybalchenko V.; Pyrrole derivatives as potential anti-cancer therapeutics: Synthesis, mechanisms of action, safety. J Drug Target 2020,28(5),547-563","journal-title":"J Drug Target"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/jm8001185","volume":"51","author":"Peifer C.","year":"2008","unstructured":"Peifer C.; Selig R.; Kinkel K.; Ott D.; Totzke F.; Sch&#xE4;chtele C.; Heidenreich R.; R&#xF6;cken M.; Schollmeyer D.; Laufer S.; Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. J Med Chem 2008,51(13),3814-3824","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bioorg.2018.06.003","volume":"80","author":"Abdelbaset M.S.","year":"2018","unstructured":"Abdelbaset M.S.; Abuo-Rahma G.E.A.; Abdelrahman M.H.; Ramadan M.; Youssif B.G.M.; Bukhari S.N.A.; Mohamed M.F.A.; Abdel-Aziz M.; Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors. Bioorg Chem 2018,80,151-163","journal-title":"Bioorg Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2174\/1871520617666170102152928","volume":"17","author":"Fatahala S.S.","year":"2017","unstructured":"Fatahala S.S.; Mohamed M.S.; Youns M.; Abd-El Hameed R.H.; Synthesis and evaluation of cytotoxic activity of some pyrroles and fused pyrroles. Anticancer Agents Med Chem 2017,17(7),1014-1025","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=27","first-page":"29","volume":"9","author":"Abd El-Hameed R.H.","year":"2018","unstructured":"Abd El-Hameed R.H.; Sayed A.I.; synthesis of novel pyrrolopyrimidine derivatives as CDK2 inhibitors. Pharmacophore 2018,9(5),29-49","journal-title":"Pharmacophore"},{"key":"ref=28","first-page":"1","volume":"21","author":"Awad S.M.","year":"2021","unstructured":"Awad S.M.; Mohamed M.S.; Khodair M.A.; Abd El-Hameed R.H.; Synthesis and evaluation of cytotoxic activity of certain benzo[h]chromene derivatives. Anticancer Agents Med Chem 2021,21,1-24","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cjoc.19960140509","volume":"14","author":"Soliman A.Y.","year":"1996","unstructured":"Soliman A.Y.; Attia I.A.; Salem M.A.; Soliman E.A.; Gaber A.M.; synthesis and reactions of 2-[&#x3B1;-(3,4-disubstituted phenacyl)-p-substitutedstyryl]-4H-3,1-benzoxazin-4-ones. Chin J Chem 1996,14(5),437-446","journal-title":"Chin J Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/ACSJ\/2016\/23961","volume":"13","author":"Soliman F.M.A.","year":"2016","unstructured":"Soliman F.M.A.; Dawoud N.T.A.; Abdel-Ghaffar N.F.; El-Guindy M.I.; Naguib H.; Synthesis, characterization and antimicrobial activity of some new heterocyclic compounds incorporating pyridazine moiety. Am Chem Sci J 2016,13(1),1-14","journal-title":"Am Chem Sci J"},{"key":"ref=31","first-page":"1549","volume":"25","author":"Abd Alla M.M.","year":"1980","unstructured":"Abd Alla M.M.; Soliman E.A.; Hamed A.A.; Osman M.W.; Cheminform abstract: Reactions of some arylidenefuranones. Rev Roum Chim 1980,25(11-12),1549-1560","journal-title":"Rev Roum Chim"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/513481a","volume":"513","author":"Baell J.","year":"2014","unstructured":"Baell J.; Walters M.A.; Chemistry: Chemical con artists foil drug discovery. Nature 2014,513(7519),481-483","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/jm00120a002","volume":"31","author":"Evans B.E.","year":"1988","unstructured":"Evans B.E.; Rittle K.E.; Bock M.G.; DiPardo R.M.; Freidinger R.M.; Whitter W.L.; Lundell G.F.; Veber D.F.; Anderson P.S.; Chang R.S.L.; Lotti V.J.; Cerino D.J.; Chen T.B.; Kling P.J.; Kunkel K.A.; Springer J.P.; Hirshfield J.; Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988,31(12),2235-2246","journal-title":"J Med Chem"},{"key":"ref=34","unstructured":"NCI website, Available from: http:\/\/www.dtp.nci.nih.gov"},{"key":"ref=35","unstructured":"NCI methodology, Available from: https:\/\/dtp.cancer.gov\/discovery_development\/nci-60\/methodology.htm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cbpa.2010.02.018","volume":"14","author":"Welsch M.E.","year":"2010","unstructured":"Welsch M.E.; Snyder S.A.; Stockwell B.R.; Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010,14(3),347-361","journal-title":"Curr Opin Chem Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.3390\/ijms21093267","volume":"21","author":"H&#xFC;bbers A.","year":"2020","unstructured":"H&#xFC;bbers A.; Hennings J.; Lambertz D.; Haas U.; Trautwein C.; Nevzorova Y.A.; Sonntag R.; Liedtke C.; Pharmacological inhibition of cyclin-dependent kinases triggers anti-fibrotic effects in hepatic stellate cells in vitro. Int J Mol Sci 2020,21(9),3267-3288","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1054\/bjoc.2000.1473","volume":"83","author":"Sausville E.A.","year":"2000","unstructured":"Sausville E.A.; Johnson J.I.; Molecules for the millennium: how will they look? New drug discovery year 2000. Br J Cancer 2000,83(11),1401-1404","journal-title":"Br J Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"Shoemaker R.H.","year":"2006","unstructured":"Shoemaker R.H.; The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006,6(10),813-823","journal-title":"Nat Rev Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","volume":"31","author":"Hatherley D.","year":"2008","unstructured":"Hatherley D.; Graham S.; Turner J.; Harlos K.; Stuart D.; Barclay A.N.; Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell 2008,31,266-277","journal-title":"Mol Cell"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1084\/jem.20122037","volume":"210","author":"Baba N.","year":"2013","unstructured":"Baba N.; Van V.Q.; Wakahara K.; Rubio M.; Fortin G.; Panzini B.; Soucy G.; Wassef R.; Richard C.; Tamaz R.; Lahaie R.; Bernard E.J.; Caussignac Y.; Leduc R.; Lougnarath R.; Bergeron C.; Racicot M.A.; Bergeron F.; Panzini M.A.; Demetter P.; Franchimont D.; Sch&#xE4;kel K.; Weckbecker G.; Kolbinger F.; Heusser C.; Huber T.; Welzenbach K.; Sarfati M.; CD47 fusion protein targets CD172a+ cells in Crohn\u2019s disease and dampens the production of IL-1&#x3B2; and TNF. J Exp Med 2013,210(6),1251-1263","journal-title":"J Exp Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/bmc.3370","volume":"29","author":"Sharma K.","year":"2015","unstructured":"Sharma K.; Suresh P.S.; Mullangi R.; Srinivas N.R.; Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors-review of assay methodologies and perspectives. Biomed Chromatogr 2015,29(6),803-834","journal-title":"Biomed Chromatogr"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3978\/j.issn.2305-5839.2014.08.14","volume":"2","author":"Fontanella C.","year":"2014","unstructured":"Fontanella C.; Ongaro E.; Bolzonello S.; Guardascione M.; Fasola G.; Aprile G.; Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014,2(12),123","journal-title":"Ann Transl Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.17628\/ecb.2014.3.1064-1068","volume":"3","author":"Hashem A.I.","year":"2014","unstructured":"Hashem A.I.; Abou-Elmagd W.S.I.; Abd-Elaziz A.; synthesis and reactions of some 2(3H)- and 2(5H)-furanone derivatives: A comparative study. Eur Chem Bull 2014,3(11),1064-1068","journal-title":"Eur Chem Bull"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210604103135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193858\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210604103135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T16:50:46Z","timestamp":1699116646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193858\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406417666210604103135","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}